Vitamin C can kill thyroid cancer cells by inhibiting MAPK/ERK and PI3K/AKT pathways via a ROS‐dependent mechanism. This shows that the pharmaceutical concentration of vitamin C has potential clinical use in thyroid cancer therapy. This evidence concerns the gene AKT1 and thyroid gland carcinoma.